Article
Brain Tumor
0
50
100
150
Mean ER
V
a
row min row max
id SRR579545 (b6J)SRR579546 (b6J)SRR2927735 (b6J)SRR594402 (b6J)SRR3351236 (b6J)SRR2133109 (GL261)SRR2133110 (GL261)SRR2133111 (GL261)SRR2133112 (GL261)SRR3063568 (GL261)SRR3063569 (GL261)SRR3063566 (GL261)SRR3063567 (GL261)
Mpmv9Mpmv13
Mpmv2Pmv1
Mpmv1Xmv19
Mpmv11Pmv12
Mpmv12Mpmv5
Mpmv4Mpmv10
Pmv24Pmv22
Mpmv3Pmv17
Pmv8Pmv11
Pmv15Mpmv6
Pmv14Mpmv8
Pmv6
Pmv2Pmv23
Xmv12Pmv4
Xmv13Xmv42
Xmv8Pmv18
Pmv19Pmv21
Pmv20Emv2
Xmv41Xmv43
Pmv13Pmv9
Pmv5Pmv10
Pmv7
Mpmv7Xmv9
Xmv16Pmv16
Xmv10Xmv17
Xmv15Xmv18
id
row max
Xmv15Xmv1 8
Naive Mice
inguinal lymph node
0.48%
GL261 flank
inguinal lymph node
4.55%
PE-Empty
APC-Tetramer MHC I
d
Pmv20
Emv2
Xmv41
Xmv43
Healthy Brain GL261
b c beads2.99
Lymphocytes44.4 Single Cells89.1
50K 150K 250K
0
50K
100K
150K
200K
250K
CD3+60.9
0 104
0
-10^3
103
104
105
cd433.9
cd858.4
0 104
0
-10^3
103
104
105
CD44+63.5
0 104
0
-10^3
103
104
105
1.30tet
0 104
0
-10^3
103
104
105
5
0
50K
FSC-W
FSC-A
0
-10^3
CD3-BV605
CD45-APC-Cy 7
- 103
CD4-PB
CD8-BV7 11 - 103
CD45-
APC-Cy7
CD44-PE
0
- 103
CD45-APC-Cy7
APC-Tetramer MHC I
Extended Data Fig. 6 | Validation of endogenous retrovirus EMV2 as a
tumour antigen for GL261. a, RNA-seq analysis of mouse endogenous
retrovirus elements in publicly available datasets on C57BL/6J mice brains and
GL261 cell lines from various sources. b, Quantification of endogenous
retrovirus elements in healthy brain and tumour tissue, from RNA-seq
(brain, n = 9; tumour, n = 6). c, Gating strategies for tetramer staining.
d, Mice were injected with 500,000 GL261 cells or PBS in the f lank. Seven days
after tumour inoculation, draining inguinal lymph nodes were collected and
emv2-env (Kb-restricted peptides aa 604–611 of p15E protein (KSPWFTTL))
tetramers were used to validate tumour-specific T cell proliferation. The
experiments were repeated twice independently with similar results. Data are
mean ± s.e.m.